Intermittent Fasting in Multiple Sclerosis
Status: | Recruiting |
---|---|
Conditions: | Neurology, Neurology |
Therapuetic Areas: | Neurology |
Healthy: | No |
Age Range: | 18 - Any |
Updated: | 5/30/2018 |
Start Date: | January 1, 2018 |
End Date: | December 31, 2020 |
Contact: | Laura Piccio, MD, PhD |
Email: | picciol@wustl.edu |
Phone: | 3147474591 |
Randomized Controlled Trial on Intermittent Fasting in Multiple Sclerosis
This is a randomized controlled trial that will test the effects of intermittent fasting (IF)
in subjects with relapsing-remitting MS (RRMS). The goal of this clinical trial is to acquire
objective evidence regarding whether an IF diet has beneficial effects in MS patients.Two
dietary regimens, IF and western diet, will be compared in a randomized, controlled,
single-blinded 12 week trial in RRMS patients. This is a single-center study.
in subjects with relapsing-remitting MS (RRMS). The goal of this clinical trial is to acquire
objective evidence regarding whether an IF diet has beneficial effects in MS patients.Two
dietary regimens, IF and western diet, will be compared in a randomized, controlled,
single-blinded 12 week trial in RRMS patients. This is a single-center study.
RRMS patients will be enrolled in a randomized, controlled, single-blinded 12 week trial in
which IF will be compared to a standard western diet. Patients will be recruited at the John
L. Trotter MS center and randomly assigned to either a standard western diet or an IF diet
(1:1). Enrolled subjects will complete a clinical and laboratory assessment before starting
the diet (baseline), at week 6 and at end of the study (week 12). The primary outcome will be
leptin at week 12 measured in the peripheral blood. Secondary outcomes will be: 1) peripheral
blood metabolic profiling; 2) anthropometric (body mass index and waist circumference) and
total body fat measures; 3) gut microbiota richness and composition.
which IF will be compared to a standard western diet. Patients will be recruited at the John
L. Trotter MS center and randomly assigned to either a standard western diet or an IF diet
(1:1). Enrolled subjects will complete a clinical and laboratory assessment before starting
the diet (baseline), at week 6 and at end of the study (week 12). The primary outcome will be
leptin at week 12 measured in the peripheral blood. Secondary outcomes will be: 1) peripheral
blood metabolic profiling; 2) anthropometric (body mass index and waist circumference) and
total body fat measures; 3) gut microbiota richness and composition.
Inclusion Criteria:
- Diagnosis of RRMS (2010 Mc Donald criteria).
- EDSS <6.0 and disease duration ≤ 15 years.
- On an injectable therapy for MS, glatiramer acetate (GA) or beta-interferon (beta-IFN)
for at least 3 months prior to the study and with no anticipated changes of the
medication for the 12 week study duration.
- Age ≥18 years.
- BMI > 22 and < 35 kg/m2 with stable weight in the 3 months prior to screening.
Exclusion Criteria:
- History of any chronic disease process (excluding MS) that could interfere with
interpretation of results.
- Diagnosis in the past of an eating disorder (anorexia, bulimia, or binge eating).
- Relapsing at the time of enrollment.
- On corticosteroid treatment (oral or intravenous) in the past month. Nasal
corticosteroid treatments are allowed.
- Diagnosis of diabetes or at time of OGTT (fasting glucose >126 mg/dl or > 200 mg/dl at
2 hours with a load of 75 g of glucose
- History of food allergies or food intolerance that would interfere with the study.
- History of antibiotic treatment within the past 3 months prior to enrollment
- Use of anticoagulant drugs (like Warfarin or Coumadin) that need to monitor their
intake of vegetables containing high levels of vitamin K.
- Currently on a special diet and not willing to stop at least one month prior to
enrollment
- Currently taking omega 3/fish oil supplements and not willing to stop administration
one month prior to enrollment
- Currently pregnant or plan to become pregnant within 6 months
- Current tobacco or e-cigarette smoker
We found this trial at
1
site
Saint Louis, Missouri 63110
Principal Investigator: Laura Piccio, MD, PhD
Phone: 314-747-4591
Click here to add this to my saved trials